BBIO vs K · rev $221.9M vs P/E 23, $29.03B cap
BridgeBio Pharma Inc (BBIO) versus Kellanova (K) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Kellanova (K) is a packaged foods company listed on US.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
K does not have a complete income-statement cache yet.
BBIO currently screens at market cap $13.24B. K currently screens at market cap $29.03B and trailing P/E 22.8.
Not investment advice. Open the BBIO and K stock pages for the full models.
Not investment advice.